Yangtze River Pharmaceutical Unveils Phase III Results for Novel Insomnia Drug Fazamorexant at World Sleep Congress
核心洞察
Yangtze River Pharmaceutical Group presented Phase III clinical trial results for Fazamorexant, a dual orexin receptor antagonist, at the World Sleep Congress 2025 in Singapore.
The multi-center, randomized, double-blind, placebo-controlled trial enrolled 1,034 adult insomnia patients and demonstrated rapid efficacy with favorable safety profile.
Fazamorexant showed superior performance in key sleep indicators compared to other DORAs, with no rebound insomnia or withdrawal symptoms observed.
Yangtze River Pharmaceutical Group has unveiled promising Phase III clinical trial results for Fazamorexant, a first-in-class dual orexin receptor antagonist (DORA) for insomnia treatment, at the World Sleep Congress 2025 held in Singapore. The announcement marks a significant milestone in the global development of innovative sleep disorder therapies and represents an important breakthrough for China in original new drug development.
Phase III Trial Design and Results
The pivotal clinical trial was designed as a multi-center, randomized, double-blind, and placebo-controlled Phase III study, enrolling 1,034 adult patients with insomnia to evaluate Fazamorexant's efficacy and safety profile. Dr. Zhu Wenjun, a postdoctoral fellow at Peking University People's Hospital, presented the detailed clinical data interpretation during the "Orexin/Hypocretin System: Clinical Use" session.
The results demonstrated that Fazamorexant exhibits rapid efficacy and a favorable safety profile in adult patients with insomnia. The drug showed exceptional performance across key sleep indicators, including improved sleep efficiency, shortened time to fall asleep, and decreased nighttime awakening. According to the presentation, these improvements were significantly greater compared to publicly available clinical data of other DORAs, though these comparisons are based on different clinical trial conditions.
Safety and Tolerability Profile
A notable finding from the trial was Fazamorexant's favorable safety and tolerability profile. The study revealed no observed rebound insomnia or withdrawal symptoms following discontinuation, addressing common concerns associated with sleep medications. This safety profile positions Fazamorexant as a potentially safer alternative for long-term insomnia management.
Clinical Innovation and Treatment Strategy
Professor Han Fang, former Secretary-General of the World Association of Sleep Medicine and former President of the Asian Society of Sleep Medicine from Peking University People's Hospital, highlighted Fazamorexant's unique properties as a fast-acting and short-half-life DORA. The drug not only meets the treatment needs of patients with difficulty falling asleep but also maintains sleep without affecting daytime activities.
Professor Han Fang noted that for patients who have difficulty maintaining sleep at night, a new strategy of "twice nightly dosing" could be explored, providing a pathway for individualized and precise treatment. This innovative dosing approach was widely recognized by scholars at the conference.
International Recognition and Future Collaboration
The presentation garnered significant attention from the international sleep medicine community. Professor Emmanuel Mignot, Academician of the United States National Academy of Sciences and Director of the Center for Sleep and Circadian Sciences at Stanford University, expressed interest in Fazamorexant and potential cooperation in further trials following the conference.
Regulatory Progress and Market Outlook
Yangtze River Pharmaceutical has officially submitted the new drug application (NDA) for Fazamorexant to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). With the international debut of the Phase III trial results, the company anticipates an accelerated review and registration process to initiate industrialization.
A company representative stated that Yangtze River Pharmaceutical is looking forward to providing "a safer, more effective and innovative option for global insomnia patients as soon as possible" through the accelerated development pathway.